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Abstract 
Background: Several studies suggested that hypertension is positively related to cancer incidence and mortality. In 
this study, we investigated the association between perioperative blood pressure (BP) and long‑term survival out‑
comes in patients with rectal cancer.
Methods: This study included a cohort of 358 patients with stages I–III rectal cancer who underwent a curative 
resection between June 2007 and June 2011. Both pre‑ and postoperative BPs were measured, by which patients 
were grouped (low BP: <120/80 mmHg; high BP: ≥120/80 mmHg). The survival outcomes were compared between 
these two groups. The primary endpoints were disease‑free survival (DFS) and cancer‑specific survival (CSS).
Results: Univariate analysis showed that patients with high preoperative systolic BP had lower 3‑year DFS (67.2% vs. 
82.1%, P = 0.041) and CSS rates (81.9% vs. 94.8%, P = 0.003) than patients with low preoperative systolic BP, and the 
associations remained significant in the Cox multivariate analysis, with the adjusted hazard ratios equal to 1.97 [95% 
confidence interval (CI) = 1.08–3.60, P = 0.028] and 2.85 (95% CI = 1.00–8.25, P = 0.050), respectively. Similarly, in 
postoperative evaluation, patients with high systolic BP had significantly lower 3‑year CSS rates than those with low 
systolic BP (78.3% vs. 88.9%, P = 0.032) in univariate analysis. Moreover, high pre‑ and/or postoperative systolic BP 
presented as risk factors for CSS in the subgroups of patients who did not have a history of hypertension, with and/or 
without perioperative administration of antihypertensive drugs.
Conclusions: High preoperative systolic BP was an independent risk factor for both CSS and DFS rates, and high 
postoperative systolic BP was significantly associated with a low CSS rate in rectal cancer patients. Additionally, our 
results suggest that rectal cancer patients may get survival benefit from BP control in perioperative care. However, 
further studies should be conducted to determine the association between BP and CSS and targets of BP control.
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Background
Colorectal cancer is the third leading cause of cancer-
related death in the United States [1] and the fifth lead-
ing cause of cancer-related death in China, and its annual 
incidence is increasing [2, 3]. Therefore, many clinical 
and basic research studies have focused on the develop-
ment of novel biomarkers to predict treatment outcomes 
and ensure optimal treatment allocation for patients 
with colorectal cancer [4]. Because of the increasing 
longevity rates and the increasing prevalence of obe-
sity, hypertension has become a leading global disease 
[5]. A meta-analysis demonstrated a positive associa-
tion between hypertension and all-site cancer incidence 
and mortality [6]. Moreover, many studies have reported 
this association for specific cancers, including renal car-
cinoma, which is the most common site-specific cancer 
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[7]. Additional studies have shown that colorectal can-
cer risk is positively related to elevated blood pressure 
(BP) [8–12]. However, these findings were inconsistent, 
and in previous studies patients’ BP was measured only 
at the time of baseline health examination. Furthermore, 
existing data are hampered by lack of adjustment for 
some potential confounding factors, such as tumor stage, 
tumor location, and the tumor’s histologic features.
Against this background of inconsistent results and 
study limitations, we extended these findings by exam-
ining the association of perioperative BP with long-term 
survival outcomes in rectal cancer patients treated with 
radical-intent surgery. If a positive association does 
exist, efforts to control BP in perioperative care may 
lead to extended survival for these patients, which may 




We reviewed 556 patients with stages I–III rectal cancer 
who underwent radical surgery at our institution between 
June 2007 and June 2011. Rectal cancer was defined as 
histologically proven adenocarcinoma within 15  cm of 
the anal verge and was staged according to the 7th edi-
tion of the American Joint Committee on Cancer (AJCC) 
staging system [13], with staging procedures, including 
colonoscopy, contrast-enhanced computed tomography 
(CT) scans, and magnetic resonance imaging, performed 
at the initial diagnosis in all cases. The exclusion criteria 
were as follows: (1) absence of postoperative BP meas-
ured at 6:00 a.m. on two consecutive postoperative days; 
(2) familial adenomatous polyposis; and (3) multiple pri-
mary cancers. Of the 556 patients, 198 were excluded. 
Finally, this retrospective and longitudinal cohort study 
included 358 patients eligible for analysis (Fig. 1).
Demographic data (including age, height, and weight), 
tumor location, tumor staging, the tumor’s histologic 
features, blood transfusion, preoperative serum carci-
noembryonic antigen (CEA) level, treatment regimen, 
time-to-recurrence, and cancer-specific survival (CSS) 
were collected from the Institutional Cancer Database 
and the Department of Inpatient Medical Records. The 
study was approved by the Medicine Ethics Committee 
of the Six Affiliated Hospital at Sun Yat-sen University.
Measurement of body mass index and BP
For all patients, weight was measured in light indoor 
clothing, and height was measured without shoes. 
According to the World Health Organization recom-
mendation for Asians based on obesity grade, body 
mass index (BMI) was categorized as underweight 
(BMI  <  18.5  kg/m2), normal (BMI 18.5–23  kg/m2), and 
overweight-obese (BMI ≥  23  kg/m2) [14]. Patients’ pre-
operative BP was measured when they were admitted to 
the hospital. Postoperative BP was defined as the mean 
value of two BPs measured at 6:00 a.m. on 2 consecutive 
postoperative days (days 1 and 2). Resting time before 
BP measurement ranged from 10 to 20 min, body posi-
tion was sitting or supine, and the equipment used was 
a mercury sphygmomanometer or an automatic device. 
Hazard ratios (HRs) for long-term survival were calcu-
lated by levels of systolic blood pressure (SBP), diastolic 
blood pressure (DBP), and mid-BP [(SBP + DBP)/2]; SBP 
was also assessed in each subset by sex, BMI, and hyper-
tension history. Mid-BP was primarily used because it is 
a strong predictor of cardiovascular mortality [15]. This 
measure, equally weighted for SBP and DBP, is consid-
ered an alternatively reasonable choice in the absence 
of knowledge about BP predictors in relation to rectal 
cancer. Pre- and postoperative BP results were classi-
fied using the Joint National Committee-7 definition 
of hypertension stage (BP: low <120/80  mmHg; high 
≥120/80 mmHg) [16]. All patients were grouped accord-
ing to these classifications.
Treatment
Details of chemoradiotherapy were described in our pre-
vious publication [17]. Among the 358 patients included 
in this study, 43 (12%) received neoadjuvant chemoradio-
therapy, in which a total irradiation dose of 46 Gy in 23 
fractions of 2 Gy with concomitant application of 5-fluo-
rouracil was given. At a median interval of 10.9  weeks 
(range, 6.9–17.3  weeks) after completion of chemora-
diotherapy, total mesorectal excision (TME) for rectal 
cancer was implemented. Surgical techniques included 
low anterior resection, abdominoperineal resection, and 
the Parks procedure. Perioperative assessment of TME 
quality was performed on all surgical specimens. Based 
on physician suggestions and patient decisions, patients 
received 6–8 cycles of postoperative 5-fluorouracil-
based chemotherapy, with a median interval of 4.4 weeks 
(range, 3.0–5.0 weeks).
Follow‑up
All patients were re-evaluated every 3 months for the first 
3 years after surgery, every 6 months for the next 2 years, 
and yearly thereafter. Each evaluation included a per-
tinent medical history, a physical examination (includ-
ing a rectal examination), and measurement of serum 
CEA concentration. Routine radiologic examinations 
consisting of chest radiography, abdominopelvic CT or 
ultrasonography, whole-body bone scintigraphy, and 
colonoscopy or double-contrast barium enema were per-
formed 6  months after surgery and annually thereafter. 
Cancer recurrence was detected by CEA > 5 ng/mL and/
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or a sequential CT scan with evidence of disease followed 
by histopathologic confirmation. The primary endpoints 
of this study were disease-free survival (DFS) and CSS. 
DFS was defined as the time from surgery until recur-
rence; CSS was defined as the time from surgery to death 
from rectal cancer. The designated endpoint date was July 
2014, with the interval of follow-up ranging from 3 to 
7 years. Patients were censored at their last follow-up if 
the endpoint of interest had not been met.
Statistical analyses
BPs were evaluated as both continuous and categorical 
variables using the median value. The intergroup com-
parisons of clinicopathologic variables were performed 
using the analysis of variance and Kruskal–Wallis tests 
for continuous variables (depending on the distribution 
of the continuous variables) and the Chi square and two-
tailed Fisher’s exact tests for discrete variables. Postop-
erative survival was estimated using the Kaplan–Meier 
method. A univariate screening of potential risk factors 
of mortality using the Cox proportional hazards model 
for each variable extracted from medical records was 
performed. All significant risk factors in the univariate 
analysis were included in the multivariate analyses using 
the Cox proportional hazards model to identify inde-
pendent risk factors. SBP, DBP, and mid-BP were never 
analyzed in the same model because of their multicol-
linearity. Data analysis was performed using SPSS ver-
sion 22.0 software for Windows (SPSS, Inc., Chicago, IL, 




Baseline demographic and clinicopathologic data of the 
entire cohort and each group by postoperative SBP are 
summarized in Table  1. Of the 358 patients included 
in this study, 204 were men and 154 were women, with 
a median age of 60  years (range, 21–89  years). Of the 
358 patients, 199 (55.6%) were categorized as under-
weight or normal weight, 135 (37.7%) were categorized 
as overweight or obese, and 24 (6.7%) had unknown 
Fig. 1 Flow diagram of patient selection. This diagram presents case disposition in the analysis of the association between perioperative BP and 
long‑term survival in patients with rectal cancer. BP blood pressure, FAP familial adenomatous polyposis
Page 4 of 10Yu et al. Chin J Cancer  (2016) 35:38 
Table 1 Baseline characteristics and distribution of clinicopathologic variables for the 358 patients with rectal cancer




 Median (range)a 60 (21–89) 58 (21–89) 65 (25–89) <0.001
 <60 174 (48.6) 143 (55.4) 31 (31.0) <0.001
 ≥60 184 (51.4) 115 (44.6) 69 (69.0)
BMI (kg/m2)
 Median (range)a 22.1 (13.3–35.9) 22.0 (13.3–33.8) 22.7 (14.9–35.9) 0.080
 <23 199 (55.6) 152 (58.9) 47 (47.0) 0.219
 ≥23 135 (37.7) 95 (36.8) 40 (40.0)
 Unknown 24 (6.7) 11 (4.3) 13 (13.0)
Sex 0.631
 Men 204 (57.0) 145 (56.2) 59 (59.0)
 Women 154 (43.0) 113 (43.8) 41 (41.0)
History of hypertension <0.001
 No 292 (81.6) 233 (90.3) 59 (59.0)
 Yes 66 (18.4) 25 (9.7) 41 (41.0)
History of smoking 0.001
 No 263 (73.5) 202 (78.3) 61 (61.0)
 Yes 95 (26.5) 56 (21.7) 39 (39.0)
Preoperative BP (mmHg)
 Median (range)a 123 (73–201) 120 (73–184) 135 (97–201) <0.001
 <120 107 (29.9) 94 (36.4) 13 (13.0) <0.001
 120–140 171 (47.8) 130 (50.4) 41 (41.0)
 ≥140 72 (20.1) 30 (11.6) 42 (42.0)
 Unknown 8 (2.2) 4 (1.6) 4 (4.0)
TNM stage, AJCC 0.537
 I 93 (26.0) 71 (27.5) 22 (22.0)
 II 115 (32.1) 80 (31.0) 35 (35.0)
 III 150 (41.9) 107 (41.5) 43 (43.0)
Differentiation degree 0.353
 Low 68 (19.0) 47 (18.2) 21 (21.0)
 Moderate 188 (52.5) 132 (51.2) 56 (56.0)
 High 102 (28.5) 79 (30.6) 23 (23.0)
Vascular invasion 0.782
 Negative 327 (91.3) 235 (91.1) 92 (92.0)
 Positive 31 (8.7) 23 (8.9) 8 (8.0)
Perineural invasion 0.698
 Negative 326 (91.1) 234 (90.7) 92 (92.0)
 Positive 32 (8.9) 24 (9.3) 8 (8.0)
Preoperative CEA 0.382
 Negative 252 (70.4) 185 (71.7) 67 (67.0)
 Positive 106 (29.6) 73 (28.3) 33 (33.0)
Distance from anal verge (cm) 0.831
 <5 132 (36.9) 96 (37.2) 36 (36.0)
 5–12 226 (63.1) 162 (62.8) 64 (64.0)
Intraoperative blood transfusion 0.514
 No 311 (86.9) 226 (87.6) 85 (85.0)
 Yes 47 (13.1) 32 (12.4) 15 (15.0)
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BMI. In the entire cohort, 66 patients (18.4%) had a his-
tory of hypertension and long-term regular use of anti-
hypertensive drugs; in the preoperative evaluation, 72 
(20.1%) were categorized as having systolic hyperten-
sion (SBP ≥ 140 mmHg), 171 (47.8%) as having systolic 
prehypertension (SBP  =  120–140  mmHg), 107 (29.9%) 
as having normal SBP (SBP < 120 mmHg), and 8 (2.2%) 
had unknown BP. The postoperative SBP, DBP, and mid-
BP were statistically distributed with medians of 109.5 
(80.0–171.0), 65.0 (42.5–102.0), and 87.5 (64.5–122.3) 
mmHg, respectively. The AJCC staging of rectal cancer 
in the entire cohort was distributed as 26.0%, 32.1%, and 
41.9% for stage I, II, and III, respectively. No statistically 
significant differences were found between patients with 
postoperative SBP  <  120 and  ≥  120  mmHg regarding 
demographic, morphometric, therapeutic regimen, and 
tumor characteristics; however, statistically significant 
differences were found in preoperative hypertension 
(42.0% vs. 11.6%, P < 0.001) and history of hypertension 
(41.0% vs. 9.7%, P < 0.001) between the high-postopera-
tive SBP group and the low-postoperative SBP group.
Univariate and multivariate analyses of survival
Median follow-up time was 42  months (range, 
37–85  months). Kaplan–Meier curves showed signifi-
cantly lower 3-year DFS rate (67.2% vs. 82.1%, P = 0.041) 
and CSS rate (81.9% vs. 94.8%, P =  0.003) in the high-
preoperative SBP group than in the low-preoperative SBP 
group. Similarly, patients in the high-postoperative SBP 
group had a significantly lower 3-year CSS rate (78.3% vs. 
88.9%, P = 0.032) than patients in the low-postoperative 
SBP group, whereas the difference in the DFS rate (65.1% 
vs. 75.0%, P = 0.326) was not significant (Fig. 2).
Univariate analysis showed that old age, advanced 
AJCC stage, vascular invasion, perineural invasion, 
elevated CEA level, low rectal cancer, and high pre- and 
postoperative BP were all significantly associated with 
increased mortality (Tables 2, 3). Specifically, HRs for BP 
and survival for total cases and for patients in each subset 
are shown in Table 3. In preoperative evaluation, patients 
with high SBP had lower 3-year DFS and CSS rates com-
pared with patients with low SBP, the HRs of which were 
1.87 (95% CI, 1.11–3.17, P  =  0.019) and 4.18 (95% CI, 
1.48–11.83, P  =  0.007), respectively; in postoperative 
evaluation, these HRs for SBP were 1.26 (95% CI, 0.79–
1.98, P = 0.330) and 1.99 (95% CI, 1.05–3.78, P = 0.035), 
respectively. The HR of the CSS rate for postoperative 
mid-BP was 2.34 (95% CI 1.16–4.72, P = 0.018).
In multivariate analysis, old age, advanced AJCC stage, 
perineural invasion, low rectal cancer, adjuvant treatment 
regimen, and high preoperative SBP (adjusted HR = 1.97, 
95% CI  =  1.08–3.60, P  =  0.028) were still significantly 
associated with 3-year DFS rate. Advanced AJCC stage, 
elevated preoperative CEA level, low rectal cancer, adju-
vant treatment regimen, and high preoperative SBP 
(adjusted HR = 2.85, 95% CI = 1.00–8.25, P = 0.050) had 
independently significant prediction value on 3-year CSS. 
Nevertheless, postoperative SBP did not remain signifi-
cant in the model for either DFS or CSS (Table 4).
Analyses on subsets of patients without history 
of hypertension
Further subset analyses were conducted to determine 
if the above association between perioperative BP and 
survival depends on the long-term negative effect of 
patients’ history of hypertension on tumorigenesis and 
cancer mortality. For 292 patients without a history of 
hypertension, the HRs of CSS for pre- and postopera-
tive SBP were 3.84 (95% CI, 1.34–11.05, P = 0.012) and 
2.77 (95% CI, 1.36–5.66, P = 0.005), respectively, whereas 
SBP systolic blood pressure, BMI body mass index, BP blood pressure, AJCC American Joint Committee on Cancer, CEA carcinoembryonic antigen
a These values are presented as median followed by a range in the parentheses; other values are presented as the number of cases with a percentage in the following 
parentheses
Table 1 continued
Variable Overall population Postoperative SBP (mmHg) P value
<120 ≥120
(n = 358) (n = 258) (n = 100)
Estimation of blood loss in operation [median (range); mL]a 100 (15–3000) 100 (20–3000) 100 (15–1000) 0.899
Adjuvant treatment 0.122
 No 177 (49.4) 121 (46.9) 56 (56.0)
 Yes 181 (50.6) 137 (53.1) 44 (44.0)
Neoadjuvant treatment 0.146
 No 315 (88.0) 223 (86.4) 92 (92.0)
 Yes 43 (12.0) 35 (13.6) 8 (8.0)
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these associations were not significant in patients with a 
history of hypertension (Table  3). To further validate if 
the verified association with cancer risk depends on the 
negative effect of antihypertensive drugs, we excluded 86 
patients with a history of hypertension and/or periop-
erative administration of antihypertensive drugs (Fig. 1); 
the survival outcomes were compared between the low-
SBP group and the high-SBP group. In the analyses of the 
remaining 272 patients, the HRs were 3.36 (95% CI, 1.15–
9.84, P = 0.027) and 2.15 (95% CI, 0.71–3.39, P = 0.076), 
respectively.
Other associations of SBPs were analyzed for DFS and/
or CSS among the subsets by sex and BMI (Table 3). In 
men, the HR of CSS for postoperative SBP was 3.37 (95% 
CI, 1.00–11.39, P = 0.050), whereas in women, the asso-
ciation was not significant. Interestingly, neither pre- nor 
postoperative SBP was significantly associated with sur-
vival in 135 patients with a BMI ≥ 23 kg/m2.
Discussion
Our study showed that perioperative BP is negatively 
associated with survival outcome in patients with rectal 
cancer. In agreement with our hypothesis, 3-year CSS 
was associated with high pre- and postoperative BP in 
patients with rectal cancer treated with radical surgery, 
and high preoperative SBP was an independent risk fac-
tor. These findings were confirmed after we stratified 
patients and only looked at the tumors of patients with-
out a history of hypertension.
The role of high BP as a possible risk factor for cancer 
mortality was first proposed in 1975 by Dyer et  al. [10] 
and has since been examined in various cohort studies. In 
most studies, BP was measured at the time of the baseline 
health examination when patients were enrolled, and to 
date only Park’s study—on renal carcinoma—addressed 
the association between perioperative BP and mortality 
[18]. However, the investigators examined the association 
Fig. 2 Kaplan–Meier survival curves of rectal cancer patients with different preoperative and postoperative BPs. The curves showed significantly 
lower DFS (a) and CSS (b) rates in the high‑preoperative SBP group than in the low‑preoperative SBP group. Patients in the high‑postoperative 
SBP group had significantly lower CSS (d) rates, whereas the differences in the DFS curves (c) were not significant. SBP systolic blood pressure, DFS 
disease‑free survival, CSS cancer‑specific survival
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between perioperative BP and renal carcinoma mortal-
ity without stratification by history of hypertension and 
adjustment for some potential confounding factors. Since 
it is well established that hypertension has an unfavorable 
effect on tumorigenesis and cancer mortality over a long 
period of time and that a history of hypertension is posi-
tively linked with perioperative BP, Park’s study was not 
able to determine the association between perioperative 
BP and cancer risk. In our analyses on subsets of patients 
without a history of hypertension, the remained associa-
tion between high perioperative SBP and CSS risk indi-
cated that the efforts to control BP in perioperative care 
may extend survival for this population. However, we 
did not exclude the possibility that undiagnosed hyper-
tension and hypertension developed after the surgery 
affected our results. Moreover, the targets for BP control 
should be determined in a larger cohort.
Many large trials have provided unassailable evidence 
that antihypertensive therapy lowers cardiovascular 
morbidity and mortality [19–21]. However, not all stud-
ies have demonstrated a significant association between 
antihypertensive treatment and overall mortality [22]; 
indeed, others have reported that the association is 
diminished over time [20]. Since then, many studies 
continued to report a putative link between antihyper-
tensive drugs and cancer, with diuretics being the most 
frequently cited suspect. These findings thus prompt 
the question: is high BP associated with increased can-
cer mortality, or is the use of antihypertensive therapy 
implicated? After excluding the patients with a history of 
hypertension and perioperative administration of anti-
hypertensive drugs, the analyses were repeated in our 
study. The results remained virtually unchanged. Since 
our results from a series of subset analyses suggested 
cancer mortality is associated with perioperative high BP, 
diuretics could be substituted for other classes of anti-
hypertensive drugs, although diuretics are currently rec-
ommended as the first-line treatment for patients with 
hypertension [23].
The biological mechanisms that could account for the 
association between hypertension and elevated can-
cer mortality remain unclear. Studies have suggested 
that hypertension and malignancy might share several 
common biochemical pathways leading to prolifera-
tive abnormalities in vascular smooth muscle cells [24], 
increased level of inositol triphosphate and cytosolic 
calcium [25], and abnormalities in carcinogen binding 
to DNA in lymphocytes [26], which are associated with 
Table 2 Univariate analysis of prognostic factors for DFS and CSS
DFS disease-free survival, CSS cancer-specific survival, HR hazard ratio, CI confidence interval, SBP systolic blood pressure, BMI body mass index, BP blood pressure, 
AJCC American Joint Committee on Cancer, CEA carcinoembryonic antigen
Factor DFS CSS
3‑year rate (%) HR (95% CI) P 3‑year rate (%) HR (95% CI) P
Age – 1.00 (0.99–1.02) 0.644 – 1.03 (1.01–1.06) 0.016
TNM stage, AJCC
 III 60.3 3.94 (1.95–7.99) <0.001 79.7 5.24 (1.58–17.42) 0.007
 II 79.7 1.81 (0.82–4.01) 0.142 86.6 3.14 (0.88–11.24) 0.079
 I 84.4 1.00 94.7 1.00
Vascular invasion
 Positive 59.3 1.93 (1.10–3.39) 0.021 77.6 1.70 (0.71–4.07) 0.234
 Negative 73.7 1.00 86.7 1.00
Perineural invasion
 Positive 38.0 3.44 (1.98–5.98) <0.001 73.8 2.45 (1.02–5.90) 0.046
 Negative 75.4 1.00 87.0 1.00
Preoperative CEA (ng/mL)
 >5 63.9 1.59 (1.00–2.52) 0.050 75.2 2.91 (1.48–5.71) 0.002
 0–5 77.2 1.00 92.2 1.00
Distance from anal verge (cm)
 5–12 75.5 0.59 (0.37–0.92) 0.021 89.3 0.47 (0.24–0.92) 0.028
 <5 69.3 1.00 82.0 1.00
Adjuvant treatment
 Yes 77.6 0.76 (0.49–1.18) 0.226 90.0 0.49 (0.25–0.94) 0.031
 No 67.2 1.00 80.7 1.00
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both hypertension and tumorigenesis. Furthermore, fac-
tors related to hypertension, such as age, smoking, and 
alcohol consumption, might contribute to increased can-
cer mortality. However, these hypotheses and findings 
could not account for the involvement of high periop-
erative SBP that is independent of a history of hyperten-
sion in cancer mortality. Therefore, we hypothesized that 
surgical procedures may augment the release of cancer 
cells into circulation [27], and then high BP in the perio-
perative period might enable the circulating cancer cells 
to penetrate blood vessels, which partially contributes to 
local recurrence, distant metastasis, and cancer-specific 
death.
Our results indicate that the cancer-specific death risk 
of high SBP is higher and statistically significant in men 
and in patients with a low BMI, which is consistent with 
the findings from previous study of all-site cancer and 
colorectal cancer [6]. Male sex, BMI, elevated periopera-
tive BP, and hypertension can be related, with a possibil-
ity of a more complex pattern among these factors in the 
risk of cancer-specific death.
Nevertheless, our study does have limitations. First, 
regarding the subgroup analyses, we were not able to 
determine the patients’ precise overall use of antihyper-
tensive drugs; therefore, the quantification of risks as 
presented may not be valid. Second, this was a retrospec-
tive study and thus was limited by unknown confounders 
owing to its observational nature, although some vari-
ables were controlled. Although BP was predictive in our 
study, future studies in larger or prospective cohorts are 
necessary to validate the association.
Conclusions
This study showed that high preoperative SBP was an 
independent risk factor for both CSS and DFS and that 
high postoperative SBP was significantly associated with 
poor CSS. Furthermore, our subset analyses suggested 
that the unfavorable effect of high BP is independent of a 
patient’s history of hypertension and use of antihyperten-
sive drugs. Additionally, our results suggest that patients 
with rectal cancer may get survival benefit from BP con-
trol in perioperative care. However, future studies should 
determine this association and identify the targets of BP 
control.
Authors’ contributions
JPW, HCY, and YXL conceived and designed the study. HCY, ZHY, and XLW 
collected the data. HCY, HP, YXL, LK, MJH, and LW analyzed and interpreted the 
data. HCY, YXL, HP, and LW drafted the manuscript. JPW revised the manuscript 
critically for important intellectual content. All authors read and approved the 
final manuscript.
Author details
1 Department of Colon and Rectum Surgery, The Sixth Affiliated Hospital 
(Guangdong Gastrointestinal and Anal Hospital), Sun Yat‑sen University, 
Guangzhou, Guangdong 510655, P. R. China. 2 Guangdong Provincial Key 
Laboratory of Colorectal and Pelvic Floor Disease, The Sixth Affiliated Hospital 
(Guangdong Gastrointestinal and Anal Hospital), Sun Yat‑sen University, 
Guangzhou, Guangdong 510655, P. R. China. 
Acknowledgements
Support for this study was provided by the National Basic Research Program 
of China (973 Program) (No. 2015CB554001, JW), the National Natural 
Science Foundation of China (No. 81472257, YL; No. 81201920, YL; No. 
81502022, XW), the Natural Science Foundation of Guangdong Province (No. 
S2013010013607, YL), the Science and Technology Program of Guangzhou 
(No. 201506010099, YL), the Fundamental Research Funds for the Central 
Universities (Sun Yat‑sen University) (No. 2015ykzd10, YL; No. 13ykpy37, YL), 
and Wu Jieping Medical Foundation (320675015173 HY).
Competing interests
The authors report no proprietary or commercial interest in any product 
mentioned or concept discussed in this article. The authors declare that they 
have no competing interests.
Received: 2 August 2015   Accepted: 20 October 2015
References
 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 
2015;65:5–29.
 2. Chen WQ, Zheng RS, Zhang SW, Zeng HM, Zou XN. The incidences and 
mortalities of major cancers in China, 2010. Chin J Cancer. 2014;33:402–5.
 3. Zhou Q, Li K, Lin GZ, Shen JC, Dong H, Gu YT, et al. Incidence trends 
and age distribution of colorectal cancer by subsite in Guangzhou, 
2000–2011. Chin J Cancer. 2015;34:34.
 4. Reimers MS, Zeestraten EC, Kuppen PJ, Liefers GJ, van de Velde CJ. Bio‑
markers in precision therapy in colorectal cancer. Gastroenterol Rep (Oxf ). 
2013;1:166–83.
 5. Whitworth JA. 2003 World Health Organization (WHO)/International Soci‑
ety of Hypertension (ISH) statement on management of hypertension. J 
Hypertens. 2003;21:1983–92.
 6. Stocks T, Van Hemelrijck M, Manjer J, Bjorge T, Ulmer H, Hallmans G, et al. 
Blood pressure and risk of cancer incidence and mortality in the meta‑
bolic syndrome and cancer project. Hypertension. 2012;59:802–10.
Table 4 Multivariate analysis of prognostic factors for DFS 
and CSS
DFS disease-free survival, CSS cancer-specific survival, HR hazard ratio, CI 
confidence interval, SBP systolic blood pressure, BMI body mass index, BP blood 
pressure, AJCC American Joint Committee on Cancer, CEA carcinoembryonic 
antigen
Variable HR (95% CI) P
DFS
 Age 0.98 (0.96–0.99) 0.039
 AJCC stage III 5.71 (2.44–13.37) <0.001
 Perineural invasion 2.17 (1.09–4.32) 0.028
 Distance from anal verge ≥5 cm 0.53 (0.32–0.85) 0.009
 Adjuvant treatment 0.41 (0.23–0.71) 0.002
 Preoperative SBP ≥120 mmHg 1.97 (1.08–3.60) 0.028
CSS
 AJCC stage III 7.45 (1.65–33.64) 0.009
 Preoperative CEA >5 ng/mL 2.18 (1.03–4.61) 0.042
 Distance from anal verge ≥5 cm 0.36 (0.17–0.77) 0.009
 Adjuvant treatment 0.36 (0.17–0.78) 0.010
 Preoperative SBP ≥120 mmHg 2.85 (1.00–8.25) 0.050
Page 10 of 10Yu et al. Chin J Cancer  (2016) 35:38 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 7. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association 
between hypertension and cancer mortality. Am J Med. 2002;112:479–86.
 8. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, et al. 
Association of vascular endothelial growth factor and vascular endothe‑
lial growth factor receptor‑2 genetic polymorphisms with outcome 
in a trial of paclitaxel compared with paclitaxel plus bevacizumab in 
advanced breast cancer: ECOG 2100. J Clin Oncol. 2008;26:4672–8.
 9. Stocks T, Lukanova A, Johansson M, Rinaldi S, Palmqvist R, Hallmans G, 
et al. Components of the metabolic syndrome and colorectal cancer risk; 
a prospective study. Int J Obes (Lond). 2008;32:304–14.
 10. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood‑
pressure: a risk factor for cancer mortality. Lancet. 1975;1:1051–6.
 11. Wannamethee G, Shaper AG. Blood pressure and cancer in middle‑aged 
British men. Int J Epidemiol. 1996;25:22–31.
 12. Peeters PH, van Noord PA, Hoes AW, Grobbee DE. Hypertension, antihy‑
pertensive drugs, and mortality from cancer among women. J Hypertens. 
1998;16:941–7.
 13. Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for 
management of patients with colon and rectal cancer. a personalized 
approach to clinical decision making. Ann Oncol. 2012;23(10):2479–516.
 14. WHO, Expert Consultation. Appropriate body‑mass index for Asian popu‑
lations and its implications for policy and intervention strategies. Lancet. 
2004;363:157–63.
 15. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age‑specific rel‑
evance of usual blood pressure to vascular mortality: a meta‑analysis of 
individual data for one million adults in 61 prospective studies. Lancet. 
2002;360:1903–13.
 16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, 
et al. The seventh report of the Joint National Committee on prevention, 
detection, evaluation, and treatment of high blood pressure: the JNC 7 
report. JAMA. 2003;289:2560–72.
 17. Deng Y, Zhou J, Fang L, Cai Y, Ke J, Xie X, et al. ALDH1 is an independent 
prognostic factor for patients with stages II–III rectal cancer after receiv‑
ing radiochemotherapy. Br J Cancer. 2014;110:430–4.
 18. Park B, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM. Influence of body 
mass index, smoking, and blood pressure on survival of patients with 
surgically‑treated, low stage renal cell carcinoma: a 14‑year retrospective 
cohort study. J Korean Med Sci. 2013;28:227–36.
 19. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. 
Randomised double‑blind comparison of placebo and active treatment 
for older patients with isolated systolic hypertension. The systolic hyper‑
tension in Europe (Syst‑Eur) trial investigators. Lancet. 1997;350:757–64.
 20. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlof B, et al. 
Relation between drug treatment and cancer in hypertensives in the 
Swedish trial in old patients with hypertension 2: a 5‑year, prospective, 
randomised, controlled trial. Lancet. 2001;358:539–44.
 21. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. 
Prevention of cardiovascular events with an antihypertensive regimen 
of amlodipine adding perindopril as required versus atenolol adding 
bendroflumethiazide as required, in the Anglo‑Scandinavian cardiac 
outcomes trial‑blood pressure lowering arm (ASCOT‑BPLA): a multicentre 
randomised controlled trial. Lancet. 2005;366:895–906.
 22. SHEP Cooperative Research Group. Prevention of stroke by antihyperten‑
sive drug treatment in older persons with isolated systolic hypertension. 
Final results of the systolic hypertension in the Elderly Program (SHEP). 
JAMA. 1991;265:3255–64.
 23. James PA, Oparil S, Carter BL, Cushman WC, Dennison‑Himmelfarb C, 
Handler J, et al. 2014 evidence‑based guideline for the management of 
high blood pressure in adults: report from the panel members appointed 
to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20.
 24. Hamet P. Cancer and hypertension: a potential for crosstalk. J Hypertens. 
1997;15:1573–7.
 25. Meyer P. Increased intracellular calcium: from hypertension to cancer. J 
Hypertens Suppl. 1987;5:S3–4.
 26. Norden A, Schersten B, Thulin T, Pero RW, Bryngelsson C, Mitelman F. 
Letter: hypertension related to D.N.A. repair synthesis and carcinogen 
uptake. Lancet. 1975;2:1094.
 27. Lundy J. Anesthesia and surgery: a double‑edged sword for the cancer 
patient. J Surg Oncol. 1980;14:61–5.
